An open label, randomised, two period, two treatment, cross over study to compare pharmacokinetics and anticoagulant effects of Rivaroxaban and Apixaban at doses approved for stroke prevention in nonvalvular atrial fibrillation patients

Trial Profile

An open label, randomised, two period, two treatment, cross over study to compare pharmacokinetics and anticoagulant effects of Rivaroxaban and Apixaban at doses approved for stroke prevention in nonvalvular atrial fibrillation patients

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Apixaban
  • Indications Stroke
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 22 Aug 2017 New trial record
    • 14 Aug 2017 Results published in the Journal of Thrombosis and Haemostasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top